Lung Cancer Trials Ask AI to find trials
CompletedPhase 1NCT00585195
Official study title

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Study summary

PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedPF-02341066 and Rifampin

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · ALK · MET

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 8, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?29 U.S. locations

Locations may change over time.

Who runs it?Pfizer

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Pfizer
Interventions being studied
Drug: PF-02341066; Drug: Rifampin; Drug: Itraconazole
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Biomarkers
ALK→MET→
Treatment approach
Targeted therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Advanced malignancies (except leukemias), histologically proven at diagnosis; Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS
  • Solid tumors must have measurable disease (Recommended Phase 2 Dose Cohort patients with non-measurable disease may enter on a case-by-case basis); not required for DDI sub-studies.
  • Adequate blood cell counts, kidney function, liver function and Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG score of 2 may be allowed on a case-by-case basis)
Reasons someone may not be able to joinExclusion criteria
  • Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of starting study treatment, depending on the patient cohort
  • Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma
  • Active or unstable cardiac disease or heart attack within 3 months of starting study treatment

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of California, Irvine Medical CenterOrange, California
  • University of Colorado Hospital/ Anschutz Cancer PavilionAurora, Colorado
  • University of Colorado HospitalAurora, Colorado
  • University of ColoradoAurora, Colorado
  • University of ChicagoChicago, Illinois
  • Massachusetts General HospitalBoston, Massachusetts
  • Ophthalmic Consultants of Boston Inc.Boston, Massachusetts
  • Beth Israel Deaconess Medical CenterBoston, Massachusetts
  • Dana Farber Cancer CenterBoston, Massachusetts
  • Joslin Beetham Eye InstituteBoston, Massachusetts
  • Karmanos Cancer InstituteDetroit, Michigan
  • Kresge Eye InstituteDetroit, Michigan

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 8, 2023. Always confirm current availability with the study team.

View original record ↗